MRI utilization in radiation therapy treatment planning continues to see steady growth. Between 2006 and 2018 its utilization increased from 6% to 24%.1 The MAGNETOM RT Pro edition for MAGNETOM Sola and MAGNETOM Vida, the first MR scanners with BioMatrix Technology, addresses the challenges of patient variability for RT treatment planning. MAGNETOM Sola and MAGNETOM Vida deliver excellent soft-tissue contrast as well as imaging that can yield information for physicians regarding tumor extent and functional parameters. Efficiently integrating this additional modality into existing processes can add substantial value to radiotherapy and help advance your institution’s clinical capabilities.